New global partnership launched to fight future pandemics
The Government will launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
Updated: 20 April 2021
:: International Pandemic Preparedness Partnership (PPP) will support PM’s target to slash the time to develop vaccines for new diseases to 100 days
:: Partnership will be chaired by UK Chief Scientific Adviser Sir Patrick Vallance and will report to leaders at June’s G7 Summit
:: New £16m funding to Coalition for Epidemic Preparedness Innovations (CEPI) will also support global vaccine supply and development
The [U.K.] Government will today (20 April) launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
The PPP will advise the UK G7 Presidency on how to meet the Prime Minister’s ambition to slash the time to develop and deploy high quality vaccines for new diseases from 300 to 100 days, backed by additional funding to support CEPI’s work on global vaccine supply. It will be chaired by the Government’s Chief Scientific Adviser Sir Patrick Vallance.
The public-private partnership will bring together industry, international organisations and leading experts. They will provide recommendations for delivering ambitious targets to more quickly develop vaccines, therapeutics and diagnostics through greater global co-operation on research and development, manufacturing, clinical trials and data-sharing.
The £16 million investment will fund global vaccine manufacturing capacity and critical research and development to rapidly respond to the threat of new strains, supporting the development of new variant-specific vaccines. CEPI’s work to coordinate research, development and manufacturing of vaccines will aid efforts to have millions of doses of vaccine available for emergency use 100 days from a variant of concern being identified.
The PPP is meeting formally for the first time today at a two day virtual Pandemic Preparedness Partnership Conference, taking place under the UK’s Presidency of the G7…
…There 20 members of the PPP include WHO Vaccines Envoy Sir Andrew Witty, Professor of Medicine at the University of Oxford & member of the Bill & Melinda Gates Foundation Scientific Advisory Committee, Sir John Bell, Managing Director of the COVAX Facility Gavi, Aurelia Nguyen, and Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI) Richard Hatchett.
Industry members include representatives from leading vaccine developers and life sciences companies such as Head of Global Drug Development and Chief Medical Officer at Novartis, John Tsai, Executive Vice President Biopharmaceuticals R&D at AstraZeneca, Sir Mene Pangalos, Chief Scientific Officer at Pfizer, Mikael Dolsten and Chief Scientific Officer at Johnsen & Johnsen, Paul Stoffels.
These experts will be joined by scientific advisers from our G7 partners, who will play a key role in shaping the recommendations into an actionable roadmap over the next two months through a series of meetings ahead of the June Leader’s Summit…